Wednesday, April 24, 2024
HomeFunding NJ-based BioCentriq Secures $29.2M in Series A Round Funding

[Funding alert] NJ-based BioCentriq Secures $29.2M in Series A Round Funding

NJ-based BioCentriq secures $29.2M in series A round funding. In terms of BioCentriq's goal of translating, refining, and scaling processes for GMP manufacture in order to speed up the delivery of novel cell therapies, the funding round represents a major turning point.
Team of BioCentriq

NJ-based BioCentriq secures $29.2M in series A round funding. In terms of BioCentriq’s goal of translating, refining, and scaling processes for GMP manufacture in order to speed up the delivery of novel cell therapies, the funding round represents a major turning point.

With this capital infusion, BioCentriq is well-positioned to fast-track its inventive capacity to deliver end-to-end With this capital infusion, BioCentriq is well-positioned to further accelerate the development and manufacturing of end-to-end solutions for cell therapy, demonstrating its innovative capabilities.

Read also – CA-based Hyperlink Ventures Secures it’s First fund at $32M

In order to meet the growing demand for scalable cell therapy solutions, the money will be wisely allocated to expand BioCentriq’s skilled team of experts, upgrade its cutting-edge facilities, and make investments in cutting-edge technologies.

James Park, BioCentriq Interim CEO and Chairman of the Board said, “We are thrilled to announce the successful completion of our latest fundraising round, which reflects the confidence of our investors in BioCentriq’s vision and capabilities,”This capital injection positions us strongly to continue driving innovation in cell therapy development, enabling our partners to bring transformative treatments to patients around the world.”

With growing interest and investment in cell therapy, the successful fundraising round coincides with a significant turning point in the field. With more resources at its disposal, BioCentriq is well-positioned to take advantage of this momentum and advance the development and production of cell-based therapeutics.

Read also – ME-based Biochar Producer Standard Biocarbon Secures $5M in Funding

About BioCentriq

With a track record of effectively transferring, developing, and producing GMP drug products for use in clinical trials, BioCentriq is a world leader in cell therapy contract development and manufacturing.

 Read also – CA-based Vasa Therapeutics Secures a Seed Funding

With cutting-edge facilities, cutting-edge technology, and a staff of highly skilled experts, BioCentriq is committed to pushing the boundaries of cell therapy innovation and assisting its partners in providing patients all over the world with treatments that can change their lives.

- Advertisement -
RELATED ARTICLES
- Advertisment -

Most Popular